77087-60-6

Usage

Uses

Used in Organic Synthesis:
3-[[(1,1-Dimethylethoxy)carbonyl]amino]-L-alanine methyl ester is used as a synthetic intermediate for the preparation of various organic compounds. Its Boc protecting group allows for selective deprotection and functionalization of the amino group, while the methyl ester group can be hydrolyzed to form carboxylic acid derivatives. 3-[[(1,1-Dimethylethoxy)carbonyl]amino]-L-alanine methyl ester is particularly useful in the synthesis of complex organic molecules, including pharmaceuticals, agrochemicals, and other specialty chemicals.
Used in Peptide Synthesis:
In the field of peptide chemistry, 3-[[(1,1-Dimethylethoxy)carbonyl]amino]-L-alanine methyl ester serves as a building block for the assembly of peptide sequences. The Boc group provides a stable and easily removable protecting group for the amino function, facilitating the stepwise elongation of peptide chains. The methyl ester group can be selectively hydrolyzed to introduce a carboxylic acid functionality at the C-terminus of the peptide, which is crucial for further conjugation or modification.
Used in Medicinal Chemistry:
3-[[(1,1-Dimethylethoxy)carbonyl]amino]-L-alanine methyl ester is employed as a key component in the design and synthesis of bioactive molecules with potential therapeutic applications. Its unique structural features enable the development of novel drug candidates with improved pharmacokinetic properties, selectivity, and potency. 3-[[(1,1-Dimethylethoxy)carbonyl]amino]-L-alanine methyl ester can be incorporated into various drug discovery programs, including those targeting infectious diseases, neurological disorders, and cancer.
Used in Chemical Research:
In academic and industrial research settings, 3-[[(1,1-Dimethylethoxy)carbonyl]amino]-L-alanine methyl ester is utilized as a versatile reagent for exploring new chemical reactions and synthetic methodologies. Its reactivity and functional group compatibility make it an attractive candidate for studying reaction mechanisms, developing new catalysts, and optimizing synthetic routes to complex organic targets.

InChI:InChI=1/C9H18N2O4/c1-9(2,3)15-8(13)11-5-6(10)7(12)14-4/h6H,5,10H2,1-4H3,(H,11,13)/t6-/m0/s1

Upstream product

• 20610-20-2 2,3-Diaminopropionic acid methyl ester 
• 24424-99-5 di-tert-butyl dicarbonate 
• 18635-45-5 D,L-α,β-diaminopropionic acid monohydrobromide 
• 6059-44-5 (L)-2,3-diaminopropionic acid methyl ester dihydrochloride 
• 58457-98-0 methyl (2S)-2-{[(benzyloxy)carbonyl]amino}-3-[(tert-butoxycarbonyl)amino]propanoate 
• 162558-25-0 N-α-tert-butoxycarbonyl-N-β-(9-fluorenylmethoxycarbonyl)-L-diaminopropionic acid 
• 16947-86-7 N^α-Tosyl-N^β-(tert-butpxycarbonyl)-L-α,β-diamonopropionic acid 
• 16947-84-5 N-[(benzyloxy)carbonyl]-3-[(tert-butoxycarbonyl)amino]-L-alanine 
• 1070-19-5 N-(tert-butyloxycarbonyl) azide 
• 126046-25-1 (S)-3-Benzyloxycarbonyl-4-<(N-tert-butoxycarbonyl)aminomethyl>-5-oxazolidinone 
• 74536-29-1 (S)-2-amino-3-((tert-butoxycarbonyl)amino)propanoic acid 

Downstream Products

• 1093189-62-8 3-tert-butoxycarbonylamino-2-(4-iodobenzoylamino)propionic acid methyl ester 
• 126046-29-5 (S)-3-tert-Butoxycarbonylamino-2-((S)-3,3,3-trifluoro-2-methoxy-2-phenyl-propionylamino)-propionic acid methyl ester 
• 126046-28-4 (S)-3-tert-Butoxycarbonylamino-2-((R)-3,3,3-trifluoro-2-methoxy-2-phenyl-propionylamino)-propionic acid methyl ester 
• 77087-64-0 methyl N-(benzyloxycarbonyl)glycyl-L-phenylalanyl-D-prolyl-N^β-(tert-butoxycarbonyl)-L-α,β-diaminopropanoate 
• 197092-14-1 3-tert-butoxycarbonylamino-2-(toluene-3-sulfonylamino)-propionic acid methyl ester 
• 1026810-59-2 2-(2-bromo-benzenesulfonylamino)-3-tert-butoxycarbonylamino-propionic acid methyl ester 
• 156185-58-9 (S)-methyl-3-((tert-butoxycarbonyl)amino)-2-(phenylsulfonamido)propanoate 
• 1026158-73-5 3-tert-butoxycarbonylamino-2-(4-chloro-benzenesulfonylamino)-propionic acid methyl ester 
• 77100-18-6 cyclo(glycyl-L-phenylalanyl-D-prolyl-N^β-(tert-butoxycarbonyl)-L-α,β-diaminopropanoyl) 
• 77087-66-2 (S)-2-({(R)-1-[(S)-2-(2-Amino-acetylamino)-3-phenyl-propionyl]-pyrrolidine-2-carbonyl}-amino)-3-tert-butoxycarbonylamino-propionic acid 2,4,5-trichloro-phenyl ester 
• 77087-65-1 (S)-2-({(R)-1-[(S)-2-(2-Benzyloxycarbonylamino-acetylamino)-3-phenyl-propionyl]-pyrrolidine-2-carbonyl}-amino)-3-tert-butoxycarbonylamino-propionic acid 2,4,5-trichloro-phenyl ester 
• 721927-33-9 benzyl (1S)-1-{[(tert-butoxycarbonyl)amino]methyl}-2-(dimethylamino)-2-oxoethylcarbamate 
• 1003577-88-5 (S)-methyl 3-[(tert-butoxycarbonyl)amino]-N-[(4-ethoxyphenyl)carbonyl]alaninate 
• 1003579-30-3 (S)-methyl 3-[(tert-butoxycarbonyl)amino]-N-{[1-phenyl-3-(trifluoromethyl)-1H-pyrazol-4-yl]carbonyl}alaninate 

Relevant academic research and scientific papers

NOVEL IMIDAZOPYRAZINE DERIVATIVES

The invention provides novel imidazopyrazine derivatives having the general formula (I), wherein Rx and R3 to R5 are as described herein (formula (I)) or pharmaceutically acceptable salts thereof. Further provided are pharmaceutical compositions including the compounds, processes of manufacturing the compounds and methods of using the compounds as medicaments, in particular methods of using the compounds as antibiotics for the treatment or prevention of bacterial infections and resulting diseases.

Sulfate Encapsulation in Supramolecular Structures from L -Asparagine-Derived 2,5-Diketopiperazine Scaffolds: Anion Binding

We report a new sulfate receptor, anchored onto 2,5-diketopiperazine units, which results in the formation of two types of supramolecules; one in which the sulfate ion guest fits snugly into extended cavities and the other in which the guest is sandwiched between layers. In each case, the anion is held by six hydrogen bonds from the host. 1H NMR spectroscopic solution studies enabled the construction of Job plots, and calculation of stoichiometry and association constants. These findings are of possible significance in drug design and for construction of combinatorial libraries.

LABELLED COMPOUNDS THAT BIND TO ALPHA-V-BETA-3 INTEGRIN

The present invention concerns in vivo imaging and in particular a novel in vivo imaging agent of formula (I). Also provided by the present invention is a method for the preparation of the in vivo imaging agent of the invention, and precursor compounds useful in said method. The in vivo imaging agent of the invention is useful in the diagnosis of conditions where there is a deviation from normal in the expression of integrin αvβ3.

Fluorescent non-peptidic RGD mimetics with high selectivity for αvβ3 vs αiIbβ3 integrin receptor: Novel probes for in vivo optical imaging

Integrins are heterodimeric transmembrane protein receptors consisting of different α and β subunits. αvβ3 integrins are overexpressed on many tumor cells and tumor-associated angiogenic vessels, whereas αIIbβ3 is a receptor for, e.g., fibrinogen and mediates platelet aggregation. In this study, a near-infrared fluorescent imaging probe has been designed and synthesized by conjugating fluorescent dyes to a non-peptidic, pharmacophore-based ligand, based on a molecular modeling design approach. Affinity values were determined, and in vitro cell binding assays and preliminary in vivo xenograft studies in nude mice were performed to evaluate target binding. Competition assays revealed excellent binding and selectivity to αvβ3 compared to that for αIIbβ3. In vitro, the probe showed high target binding on αvβ3-positive M-21 cells and negligible binding to αvβ3-negative MCF-7 cells. In vivo, the tracer is able to image target expression in U-87 xenografts with a maximum signal-to-noise ratio (SNR) of 2.5:1 at 24 h after injection.

Hydantoin and thiohydantoin derivatives as antiviral drugs

The present invention relates to a compound of the following formula (I), or a salt, solvate, tautomer, enantiomer, diastereoisomer or racemic mixture thereof: as well as its use as a drug, notably in the treatment of hepatitis C, its preparation process, and the pharmaceutical compositions containing such a compound.

HYDANTOIN AND THIOHYDANTOIN DERIVATIVES AS ANTIVIRAL DRUGS

The present invention relates to a compound of the following formula (I), or a salt, solvate, tautomer, enantiomer, diastereoisomer or racemic mixture thereof: as well as its use as a drug, notably in the treatment of hepatitis C, its preparation process, and the pharmaceutical compositions containing such a compound.

Compositions Comprising Enzyme-Cleavable Oxycodone Prodrug

The embodiments provide Compound KC-7, N-1-[(S)-2-(oxycodone-6-enol-carbonyl-methyl-amino)-2-carbonyl-sarcosine-ethyl amine]-arginine-glycine-acetate, or acceptable salts, solvates, and hydrates thereof. The present disclosure also provides compositions, and their methods of use, where the compositions comprise a prodrug, Compound KC-7, that provides controlled release of oxycodone. Such compositions can optionally provide a trypsin inhibitor that interacts with the enzyme that mediates the controlled release of oxycodone from the prodrug so as to attenuate enzymatic cleavage of the prodrug.

Iridium-catalyzed asymmetric allylic amination with polar amines: Access to building blocks with lead-like molecular properties

The combination of an air-stable iridium catalyst and the dipolar aprotic solvent dimethyl sulfoxide (DMSO) allowed, for the first time, the systematic exploitation of highly polar, functionalized amines in asymmetric allylic substitutions: low molecular

NOVEL ETHYLENEDIAMINE DERIVATIVES

A compound represented by the following formula (1):Q-Q-T-N(R)-Q-N(R)-T-Q [wherein, R1 and R2 are hydrogen atoms or the like; Q1 is a saturated or unsaturated, 5- or 6- membered cyclic hydrocarbon group which may have a substituent, or the like; Q2 is a single bond or the like; Q3 represents the following group: -C(R3a)(R4a)-{C(R3b)(R4b)}m1-{C(R3c)(R4c)}m2-{C(R3d)(R4d)}m3-{C(R3e)(R4e)}m4-C(R3f)(R4f)- (in which, R3a to R4e represent hydrogen or the like); T0 represents a carbonyl group or the like; and T1 represents -COCONR- or the like]; or salt thereof, solvate thereof, or N-oxide thereof. The compound is useful as a preventive and/or therapeutic agent for cerebral infarction, cerebral embolism, myocardial infarction, angina pectoris, pulmonary infarction, pulmonary embolism, Buerger's disease, deep venous thrombosis, disseminated intravascular coagulation syndrome, thrombus formation after valve or joint replacement, thrombus formation and reocclusion after angioplasty, systemic inflammatory response syndrome (SIRS), multiple organ dysfunction syndrome (MODS), thrombus formation during extracorporeal circulation, or blood clotting upon blood drawing.

Non-peptide GPIIb/IIIa inhibitors. 20. Centrally constrained thienothiophene α-sulfonamides are potent, long acting in vivo inhibitors of platelet aggregation

The synthesis and pharmacology of 4, a potent thienothiophene non- peptide fibrinogen receptor antagonist, are reported. Compound 4 inhibited the aggregation of human gel-filtered platelets with an IC50 of 8 nM and demonstrated an 8-fold improvement in affinity for isolated GPIIb/IIIa receptors over analogues possessing an isoindolinone backbone. Flow cytometry studies revealed that the binding of 4 to resting platelets is a diffusion- controlled process (k(on) = 3.3 x 106 M-1 s-1) and that 4 binds to dog and human platelets with comparable affinity (K(d) = 0.04 and 0.07 nM, respectively). Ex vivo platelet aggregation in dogs was completely inhibited by an iv dose of 5 mg/kg, and an oral dose of 50-90 mg/kg followed by low daily doses of 10 mg/kg was sufficient to maintain ~80% inhibition of ex vivo platelet aggregation over several days. Inhibition of ADP-induced platelet aggregation in anesthetized dogs at 77 ± 7% resulted in a moderate 2.5-fold increase in bleeding time, while complete inhibition (100%) resulted in an approximately 10-min bleeding time. Additional doses were required to increase the bleeding time to the maximum time allowed in the protocol (15 min), thus indicating a potentially useful and safe separation of efficacy and bleeding time.